Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (Am J Clin Dermatol, (2017), 18, (405–411), 10.1007/s40257-017-0258-0)

Carle Paul; Craig Leonardi; Alan Menter; Kristian Reich; Linda Stein Gold; Richard B. Warren; Anders Møller; Mark Lebwohl

ArticleOPEN ACCESS

Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (Am J Clin Dermatol, (2017), 18, (405–411), 10.1007/s40257-017-0258-0)

American Journal of Clinical Dermatology

DOI: 10.1007/s40257-017-0295-8

3Citations

11Readers

Abstract

In the original publication, the Fig. 2, page 408, which appeared as: (Figure presented.).

Cite

CITATION STYLE

APA

Paul, C., Leonardi, C., Menter, A., Reich, K., Gold, L. S., Warren, R. B., … Lebwohl, M. (2017, August 1). Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (Am J Clin Dermatol, (2017), 18, (405–411), 10.1007/s40257-017-0258-0). American Journal of Clinical Dermatology. Springer International Publishing. https://doi.org/10.1007/s40257-017-0295-8

Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (Am J Clin Dermatol, (2017), 18, (405–411), 10.1007/s40257-017-0258-0)

Abstract

Cite

Register to see more suggestions